IVA 337

Drug Profile

IVA 337

Alternative Names: IVA337

Latest Information Update: 29 Nov 2016

Price : $50

At a glance

  • Originator Inventiva Pharma
  • Class Antifibrotics; Skin disorder therapies
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Idiopathic pulmonary fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Systemic scleroderma
  • Preclinical Fibrosis
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 09 Nov 2016 Phase-II clinical trials in Non-alcoholic steatohepatitis in Austria (PO) (EudraCT2016-001979-70)
  • 13 Apr 2016 Pharmacodynamics data from preclinical trials in Fibrosis presented at the International Liver Congress 2016 (ILC-2016)
  • 01 Oct 2015 Phase-II clinical trials in Systemic scleroderma in France and Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top